Lipigon develops new treatments for diseases caused by disruptions in the body's handling of fats – known as lipid-related diseases. Our company's foundation is built upon over 50 years of research at Umeå University. Lipigon aims to become a world-leading player in our field and the preferred collaborative partner for big pharma.

Lipigon initially focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in clinical development. This allows for studies with fewer patients, shorter timeframes, and reduced development costs, which ultimately reduces development risks. In some cases, Lipigon can potentially attain orphan drug status to further mitigate development risks and establish a foundation for market exclusivity and competitive pricing.

Lipigon's pipeline consists of four active projects: the RNA drug Lipisense®, targeting elevated triglycerides; an RNA drug project for acute respiratory distress syndrome; a gene therapy project for the rare disease lipodystrophy in collaboration with Combigene AB (publ); and a small molecule project for dyslipidemia (general lipid disorders) in partnership with HitGen, Inc.